New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
10:45 EDTMYGN, MYGN, MYGNMyriad Genetics has a conference call hosted by JPMorgan
JPmorgan Analyst Peterson will host a conference call with CEO Pete Meldrum on April 11 at 11 am.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:51 EDTMYGNTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:08 EDTMYGNCrescendo data shows Vectra DA is better predictor of joint damage in RA
Subscribe for More Information
November 14, 2014
07:14 EDTMYGNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 10, 2014
10:04 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTMYGNMyriad Genetics initiated with an Underweight at Morgan Stanley
Subscribe for More Information
November 7, 2014
07:23 EDTMYGNMyriad myPath Melanoma study shows 43% reduction in indeterminate diagnoses
Myriad Genetics presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology, or ASDP, annual meeting in Chicago, IL. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes. Key findings of this clinical utility study included a 43% reduction in indeterminate diagnoses and a 49% change in physicians' treatment recommendations for patients. The study evaluated the impact of the Myriad myPath Melanoma diagnostic test on dermatopathologists' diagnoses and intended treatment recommendations for 218 patients with pigmented skin lesions that were considered difficult to diagnose. The dermatopathologists recorded their diagnoses and treatment plans before and after receiving the myPath Melanoma test results.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use